Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin
Go back to Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 29.41 +0.02 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $29.39 | 52 Week High | $42.49 | |||
| Open | $29.57 | 52 Week Low | $16.64 | |||
| Day High | $29.76 | P/E | N/A | |||
| Day Low | $29.10 | EPS | $-0.42 | |||
| Volume | 1,346,524 | |||||
